Verve Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Pentwater Capital Management LP and Matthew Halbower have disclosed a 7.5% beneficial ownership stake in Verve Therapeutics, Inc.
Multiple GV entities, including those affiliated with Alphabet Inc., have reported zero beneficial ownership in Verve Therapeutics, Inc. after its acquisition by Eli Lilly and Company.
Millennium Management LLC and its affiliates have reported a reduction in their beneficial ownership of Verve Therapeutics, Inc. common stock, falling below the 5% reporting threshold after briefly exceeding it.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.0% beneficial ownership stake in Verve Therapeutics, Inc. as of March 31, 2025.
State Street Corporation has filed a Schedule 13G, reporting a 3.8% passive beneficial ownership stake in Verve Therapeutics Inc. as of December 31, 2024.
SCHEDULE 13G/A: Millennium Management Entities Disclose Passive Stake Below 5% in Verve Therapeutics
Integrated Core Strategies (US) LLC and Millennium Management entities, including Israel A. Englander, have filed an amended Schedule 13G disclosing beneficial ownership of less than 5% in Verve Therapeutics, Inc. as of December 31, 2024.
ARK Investment Management LLC has filed an amended Schedule 13G, indicating it no longer holds any beneficial ownership in Verve Therapeutics, Inc. as of September 30, 2024.